Aurobindo Pharma Q1 results preview: Net profit likely to rise 13% to Rs 586 crore, margin may remain steady

Hyderabad-based drug maker Aurobindo Pharma is scheduled to report its financial results for the April-June period on Saturday, August 12. Analysts expect the pharmaceutical company to stage a quarterly strong performance driven by all-round growth.    

According to Zee Business research, Aurobindo Pharma is likely to report a consolidated net profit of Rs 586 crore for the first quarter of the current financial year, which translates to an increase of 12.7 per cent compared with the corresponding period a year ago. The analysts estimate the company to register 7.8 per cent year-on-year growth in revenue to Rs 6,726 crore for the quarter ended June 30. 

The company is expected to report Rs 1,096 crore in earnings before interest, taxes, depreciation and amortisation (EBITDA) as against Rs 1,020 crore for the year-ago period, according to the research. 

Zee Business analysts peg the pharma firm's margin — a key measure of profitability — at 16.3 per cent, the same level as last year. 

How Aurobindo Pharma performed in the March quarter 

For the last quarter of the financial year 2022-23, the drug maker exceeded analysts' estimates with a net profit of Rs 506 crore and revenue of Rs 6,473 crore, according to a regulatory filing.

Aurobindo Pharma's margin for the quarter ended March 31 came in at 16 per cent. 

Aurobindo Pharma shares

Aurobindo Pharma shares rewarded investors with a return of 40.5 per cent in the April-June period, sharply outperforming a 10.5 per cent rise in the headline Nifty index and a 14.6 per cent gain in the Nifty Pharma sectoral index.

As of August 11, the Aurobindo Pharma stock had nearly doubled in the past year while the benchmark gauge gained 9.8 per cent. 
 

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.